• CCK-8 Ammonium Mitigates Anxiety in Morphine-Withdrawal Rats

  2026-04-30

  This study demonstrates that cholecystokinin octapeptide (CCK-8) exerts a dose-dependent anxiolytic effect in morphine-withdrawal rats, mediated via endogenous opioid signaling and the CCK1 receptor. The findings identify a mechanistic link between CCK-8 and negative affect regulation during opioid abstinence, suggesting new neurobiological targets for addiction-related anxiety.

• Ridaforolimus (Deforolimus): Precision mTOR Inhibition in Ca

  2026-04-30

  Ridaforolimus (Deforolimus, MK-8669) is a benchmark mTOR inhibitor with ultra-low nanomolar potency, enabling robust anti-proliferative and anti-angiogenic studies in diverse cancer models. This article provides actionable workflows, troubleshooting strategies, and practical assay guidance, grounded in recent AI-driven senolytic discovery and comparative data.

• Catalpol in Neuroinflammation: Beyond Pathway Modulation to

  2026-04-29

  Explore how Catalpol, a natural iridoid glycoside, drives neuroprotection research through NF-κB and TrkB signaling modulation. This in-depth analysis reveals how recent breakthroughs refine practical assay parameters and experimental rigor.

• CLK2 Phosphorylation of BRCA1 Drives Platinum Resistance in

  2026-04-29

  This study identifies Cdc2-like kinase 2 (CLK2) as a key mediator of platinum resistance in ovarian cancer through phosphorylation of BRCA1 at Ser1423, enhancing DNA damage repair and reducing chemotherapy efficacy. The findings highlight a novel therapeutic target for overcoming resistance in BRCA-associated cancer and inform the design of future DNA damage response assays.

• Applied Use of the Alcian Blue & Nuclear Fast Red Staining K

  2026-04-28

  Empower your mesenchymal stem cell and mucopolysaccharide detection workflows with the Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5. This guide covers practical use cases, troubleshooting, and evidence-based enhancements to achieve reliable, high-contrast histological staining even for challenging small tissue biopsies.

• Cabozantinib (XL184): Optimizing Antiangiogenic Research Wor

  2026-04-28

  Cabozantinib (XL184) stands out as a multi-kinase inhibitor enabling detailed, timescale-sensitive dissection of tyrosine kinase signaling and adaptation in cancer models. This article delivers protocol-ready guidance, real-world troubleshooting, and translational insights from phosphoproteomics to maximize the impact of Cabozantinib in medullary thyroid and renal cell carcinoma research.

• Cholecystokinin Octapeptide Ammonium: Reliable Immunomodulat

  2026-04-27

  This article offers practical, evidence-driven guidance for deploying Cholecystokinin octapeptide ammonium (SKU C8717) in cell viability and immune modulation assays. Drawing on published data and APExBIO’s advanced formulation, it addresses real-world laboratory challenges—from protocol optimization to vendor selection—helping researchers make informed, reproducible choices.

• ISRIB (trans-isomer): Unlocking ISR Inhibition for Memory an

  2026-04-27

  This thought-leadership article dissects how ISRIB (trans-isomer) enables next-generation interrogation of the integrated stress response (ISR) in translational neuroscience and disease modeling. By blending mechanistic depth with actionable protocol guidance, it charts new territory in applying PERK inhibition to memory, neurodegeneration, and ER stress research, while offering clear, evidence-labeled recommendations for researchers.

• CDK9 Inhibitor (A3294): Technical Use and Protocol Parameter

  2026-04-26

  CDK9 inhibitor (A3294) provides researchers with a selective, non-cytotoxic tool for inhibiting cyclin dependent kinase 9, facilitating studies of transcription elongation inhibition and HIV-1 propagation. This reagent is unsuitable for protocols requiring broad-spectrum CDK inhibition or long-term storage of working solutions.

• Dual Terminal Oxidase Inhibition in Tuberculosis by Pretoman

  2026-04-25

  This study defines how pretomanid, a bicyclic nitroimidazole derivative, achieves potent bactericidal activity against Mycobacterium tuberculosis by inhibiting both cytochrome bcc:aa3 and bd terminal oxidases. The findings highlight the value of rational combination regimens targeting respiratory metabolism to suppress resistance and enhance efficacy in tuberculosis therapy.

• Applied Workflows with Hesperadin: Aurora B Kinase Inhibitor

  2026-04-24

  Hesperadin enables targeted disruption of mitotic progression and spindle assembly checkpoint fidelity, offering a robust platform for mechanistic cancer research and cell cycle dissection. This article delivers actionable protocols, troubleshooting strategies, and a translational bridge from recent checkpoint complex regulation discoveries.

• ATF4-Regulated Enhancer Inhibition Mitigates Liver Fibrosis

  2026-04-24

  This study uncovers a non-canonical, ATF4-driven enhancer program in hepatic stellate cells that promotes liver fibrosis, independent of classic ER stress pathways. Targeting ATF4 translation, the researchers demonstrate meaningful reversal of fibrosis, highlighting new molecular targets for future therapeutic development.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-04-23

  Schwartz's dissertation redefines how in vitro assays distinguish between cancer cell death and growth inhibition, demonstrating that relative and fractional viability capture distinct drug effects. These insights clarify the interpretation of apoptosis assays, supporting more precise evaluation of agents like ABT-263 (Navitoclax) in preclinical models.

• Optimizing Cell Selection with Geneticin, G-418 Sulfate (SKU

  2026-04-23

  This article delivers practical, evidence-based strategies for leveraging Geneticin, G-418 Sulfate (SKU A2513) to resolve real-world challenges in cell selection, viability assays, and antiviral research. By drawing on quantitative data and scenario-driven Q&A, we demonstrate how APExBIO’s Geneticin ensures reproducibility and sensitivity in advanced biomedical workflows.

• Disrupting the c-MYC-G9a Axis: Co-targeting BRD4 and RAC1 in

  2026-04-22

  This study demonstrates that co-inhibition of BRD4 and RAC1 suppresses growth, stemness, and tumorigenesis in diverse breast cancer subtypes by disrupting the c-MYC–G9a–FTH1 signaling axis and downregulating HDAC1. The findings reveal a mechanistic link between oncogenic signaling and epigenetic chromatin remodeling, providing a rationale for targeting these pathways in translational cancer research.

16193 records 1/1080 page Next 12345 下5页 Last page